GV2311 – RSV Vaccine

Respiratory Syncytial Virus (RSV) is an important cause of lower respiratory tract infections in the very young, the elderly, and the immunocompromised. Currently, there is no preventive vaccine available. Most children will have an RSV infection by their second birthday, and in the United States, this results in approximately 130,000 pediatric hospitalizations per year. Infection by RSV does not provide durable immunity. Existing therapies intended to inhibit the activity of the RSV virus and minimize or prevent lower respiratory tract infections are approved for only a subset of the pediatric population that is considered at high risk. However, many of the pediatric patients who are hospitalized secondary to RSV infection do not fit this profile.

In preclinical testing, GenVec's RSV vaccine candidate, GV2311, produced broad, durable RSV virus neutralization in both mice and the industry-standard cotton rat model, with protection demonstrated to at least six months. In these models, treatment protected against RSV challenge in both the upper and lower respiratory tracts, with no evidence of disease potentiation.

GV2311 was designed specifically for the prevention of RSV and its attendant complications in the very young while at the same time avoiding the potential disadvantages of subunit vaccines and live attenuated vaccines that have failed in the past. This vaccine candidate is intended to provide a durable immune response even in the presence of maternal antibodies.